Clinical trial
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant…
NCT00003034 · Alfacell, Industry · Unknown status
Key facts
| NCT number | NCT00003034 |
|---|---|
| Title | ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen |
| Official title | ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen |
| Lead sponsor | Alfacell, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | doxorubicin hydrochloride, ranpirnase |
| Enrollment | 300 |
| Start date | May 1, 1997 |
| Primary completion | Feb 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 6, 2013 |
| Countries | Germany, Italy, Poland, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: